arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

CytoDyn Inc.

CYDY
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
67
Health
Good
Bullish
auto_awesome

Analytical Summary

CytoDyn Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC 7.9%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.35
info Valuation on last close.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-9.86M
↓ -65.6%
FCF / Share Free cash flow per share
$-0.00
↓ -25.5%
Long-Term Debt Long-term obligations
$38.34M
↓ -5.4%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
93
Financial Health
51
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 24 years · 71 quarters